Drug class in one race
AT1 receptor; NPC1L1; HMG-CoA reductase drugs for Atherosclerotic Cardiovascular Disease
2 tracked AT1 receptor; NPC1L1; HMG-CoA reductase drugs in the Atherosclerotic Cardiovascular Disease race. The class explanation lives on the AT1 receptor; NPC1L1; HMG-CoA reductase page; the full indication pipeline across every mechanism is on the Atherosclerotic Cardiovascular Disease page.
2 Phase 3
Head-to-head evidence: BR1017 vs Candesartan/Rosuvastatin/Ezetimibe